Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Patients on Hemodialysis or Peritoneal Dialysis

• Published in: American journal of nephrology Vol. 28; no. 1; pp. 97 - 106
• Main Authors: Ross, Edward A., Tian, Jin, Abboud, Hanna, Hippensteel, Richard, Melnick, Joel Z., Pradhan, Rajendra S., Williams, Laura A., Hamm, L. Lee, Sprague, Stuart M.
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland S. Karger AG 01.01.2008
• Subjects: Administration, Oral; Adult; Aged; Aged, 80 and over; Calcium - blood; Ergocalciferols - administration & dosage; Ergocalciferols - adverse effects; Female; Humans; Hyperparathyroidism, Secondary - blood; Hyperparathyroidism, Secondary - drug therapy; Hyperparathyroidism, Secondary - etiology; Kaplan-Meier Estimate; Kidney Failure, Chronic - complications; Kidney Failure, Chronic - therapy; Male; Middle Aged; Original Report: Patient-Oriented, Translational Research; Parathyroid Hormone - blood; Peritoneal Dialysis; Phosphorus - blood; Placebos; Receptors, Calcitriol - metabolism; Renal Dialysis; Treatment Outcome; Chronic renal failure; Chronic renal insufficiency; Secondary hyperparathyroidism; Paricalcitol

Background/Aims: Secondary hyperparathyroidism is a common complication of chronic kidney disease, resulting from inactivation of vitamin D receptor signaling and phosphate retention. Selective activation of vitamin D receptors with intravenous paricalcitol significantly reduced parathyroid hormone...